About the Event
Join Philadelphia Business Journal healthcare reporter John George as he explores the latest developments in the Philadelphia region’s life sciences industry with a group of leading experts, including the co-founder of Spark Therapeutics, a longtime Wistar Institute researcher and scientific leader, the president of science and technology at Cabaletta Bio, and the CEO of Madrigal Pharmaceuticals, whose lead product is on track to surpass $1 billion in annual sales this year.
The Philadelphia region’s life sciences industry has produced some of the most significant medical breakthroughs of the past decade, including Spark Therapeutics receiving the first FDA approval for a gene therapy to treat an inherited disease and University of Pennsylvania researchers developing the science that led to the first FDA-approved CAR T-cell therapy for cancer. Today, however, the industry faces a new set of challenges. Private biotech companies are competing for investment capital to advance promising drug candidates, academic researchers are grappling with federal funding cuts, and payers continue to raise concerns about the cost of cutting-edge therapies.
At this year’s Philadelphia Business Journal State of the Biotech Industry event on Oct. 22, industry leaders will discuss the opportunities and obstacles shaping the sector, what they see on the horizon, and what it all means for the future of the region’s life sciences ecosystem.
